Government of India Ministry of Commerce and Industry Department of Commerce DIRECTORATE GENERAL OF FOREIGN TRADE
Meeting No - NC/3/MEET/Mar/202122/15 Meeting Date – 17/03/2022
Minutes of the Norms Committee – 3 Meeting No. NC/3/MEET/ Mar/202122/15 dated 17.03.2022, was actually held on 23.03.2022 under the Chairmanship of Dr. Amiya Chandra, Addl. DGFT for considering the cases/issues under Duty Exemption Scheme (Chapter-4) of Foreign Trade Policy, 2015-20 pertaining to Chemical and Allied products falling under Chapter 29 and 30.
Following members were present in the Meeting:
| Sl.<br>No. |
Name & Designation |
Department |
| 1 |
Shri Shaish Kumar, Technical – 1 |
Consultant |
| 2 |
Shri D.N. Mathur, Technical – 2 |
Consultant |
| In attendance |
|
|
| 1 |
Shri Ajay Kumar, Deputy Director |
DGFT |
- The Norms Committee has taken decision only with respect to technical aspect/ wastage norms. While redeeming the application, RAs should check that the applicant has fulfilled all requirements as prescribed in policy/procedure including those in policy circulars issued from time to time or any other provisions under FTP/HBP for issuance of Advance Authorization and regularization of the case.
The committee went through the minutes of earlier Meeting No. NC/3/MEET/Feb/202122/14 dated 21.02.2022, was actually held on 25.02.2022.
MANUAL CASES
| Case No. |
Case No. |
Case No. |
A-01 |
A-01 |
|
MeetingNo. |
|
NC/3/MEET/Mar/202122/15 |
|
|
|
|
1222 |
|
|
ate |
|
7.03.0 |
|
| F |
irm’s Name |
|
M/s Clean Science and Technology Private Limited |
|
|
HQF. No. |
|
<br>01/82/050/00149/AM18/DES-III |
|
| R |
LA F. No. |
|
31/83/040/00012/AM18 |
|
|
Advance Authorizati |
on No. and Date |
3110066716 dated 02.05.2017 |
|
| S |
|
|
|
|
|
ubject |
|
Request of M/s CLEAN SCIENCE AND TECHNOLOGY PVT.<br>LTD f ht i th tit f it it f i |
|
|
|
|
. or enancemen n e quany o mpor ems o norms n<br>respect of adhoc norms fixed against Advance Authorization No. |
|
|
|
|
<br>3110066716 dated 02.05.2017 |
|
| <br>f |
**Decision:**The C |
ommittee considered the request of firm and it was decided to call for following information |
|
|
|
rom the firm:<br>(i)<br>Difference between Export Product Guaicol & MEHQ, since molecular formula<br>& molecular weight remains same.<br>(ii)<br>If item of export is same, why different consumption for raw material i.e. Anisole /<br>Phenoxy Methane. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| C |
a |
se No. |
|
**A-0 ** |
2 |
|
|
|
|
|
Me |
etingNo. |
|
NC |
/3/MEET/M |
ar/2021 |
22/15 |
|
|
|
Da |
|
|
|
|
|
|
|
|
|
|
te |
|
17. |
3.2022 |
|
|
|
|
| F |
ir |
m’s Name |
|
M/s |
Clean Scien |
ces and |
Technology Pvt. Ltd., |
|
|
|
HQ |
F. No. |
|
01/8 |
2/050/02161 |
/AM19/ |
DES-III |
|
|
| R |
L |
A F. No. |
|
31/8 |
3/040/00133 |
/AM19 |
|
|
|
|
Ad |
vance Authorization No. and Date |
|
311 |
0067248 dat |
ed 10.12 |
.2018 |
|
|
| S |
u |
bject |
|
Req<br> |
uest of M/<br> |
s Clean<br> |
Sciences and Technology P<br> |
vt. Ltd. for<br> |
|
|
|
|
|
enhancement in the quantity of import item in respect of adhoc<br>norms fixed against Advance Authorization No. 3110067248 dated<br>10.12.2018 |
|
|
|
|
|
| Decision:The Committee considered the request of firm and it was decided to call for following information<br>from the firm:<br>(i)<br>Difference between Export Product Guaicol & MEHQ, since molecular formula<br>& molecular weight remains same.<br>(ii)<br>If item of export is same, why different consumption for raw material i.e. Anisole /<br>Phenoxy Methane. |
De<br>ro |
**cision:**The Committee considered the request of firm and it was decided to call for following information<br>m the firm: |
|
|
|
|
|
|
|
|
(i) |
|
Difference between Export Product Guaicol & MEHQ, since molecular formula<br> |
|
|
|
|
|
|
|
(ii) |
|
& molecular weight remains same.<br>If item of export is same why different consumption for raw material ie Anisole / |
|
|
|
|
|
|
|
|
|
, ..<br>Phenoxy Methane. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Case No. |
|
|
A-03 |
| MeetingNo. |
|
|
NC/3/MEET/Mar/202122/15 |
| Date |
|
|
17.03.2022 |
| Firm’s Name |
|
|
M/s Clean Science and Technology Private Limited |
| HQF. No. |
|
|
01/82/050/00916/AM19/DES-III |
| RLA F. No. |
|
|
31/83/040/00034/AM19 |
| Advance Authorization No. and Date |
|
|
3110067081 dated 15.06.2018 |
| Subject |
|
|
Request of M/s CLEAN SCIENCE AND TECHNOLOGY PVT. |
|
|
|
LTD. for enhancement in the quantity of import items of norms in |
|
|
|
respect of adhoc norms fixed against Advance Authorization No. |
|
|
|
3110067081 dated 15.06.2018 |
| Decision: |
The Committee considered |
|
the request of firm and it was observed that the item of export was not |
| clear in GST |
data. Hence, it was decided to call for following information from the firm: |
|
|
|
(i) |
Whether export is 4 MAP or Anisole 93%. Please clarify. |
|
| Case No. |
Case No. |
|
A-04 |
|
|
|
| MeetingNo. |
|
|
NC/3/MEET/Mar/202122/15 |
|
|
|
| Date |
|
|
17.03.2022 |
|
|
|
| Firm’s Name |
|
|
M/s OC Specialities Pvt. Ltd. |
|
|
|
| HQF. No. |
|
|
01/82/050/01370/AM21/DES-III |
|
|
|
| RLA F. No. |
|
|
03/95/040/00138/AM21 |
|
|
|
| Advance Authorization No. and Date |
|
|
0310836618 dated 10.06.2020 |
|
|
|
| Subject |
|
|
Request of M/s OC Specialities Pvt. Ltd. for enhancement in the |
|
|
|
|
|
|
quantity of import item in respect of adhoc norms |
|
fixed against |
|
|
|
|
Advance Authorization No. 0310836618 dated 10.06.2020 |
|
|
|
| **Decision:**The Committee considered the request of firm and taking into consideration the 86% yield and GST |
|
|
|
|
|
|
| data furnished by the firm, it was decided to revise adhoc<br> |
|
|
|
norms as under: |
|
|
|
Export product |
|
Qty.<br>Sl. |
Import items |
Qty. |
|
|
|
|
No. |
|
|
|
|
3-CHLORO-2-HYDRAZINO |
|
1 kg<br>1 |
2,3 DICHLORO PYRIDINE |
1.20 kg |
|
|
PYRIDINE(CHAP) |
|
2 |
HYDRAZINE HYDRATE 100 % |
1.218 kg |
|
| RA concerned maytake further necessaryaction asper above decision of NC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| C |
|
|
|
|
|
|
|
|
|
|
ase No. |
|
|
A-05 |
|
|
|
|
|
|
MeetingNo. |
|
|
NC/3/MEET/Mar/202122/15 |
|
|
|
|
|
| D |
ate |
|
|
17.03.2022 |
|
|
|
|
|
| F |
irm’s Name |
|
|
M/s Hubergroup India Private Limited |
|
|
|
|
|
| H |
QF. No. |
|
|
01/82/MISC/Para 4.06/1/AM21/DES-III |
|
|
|
|
|
| R |
LA F. No. |
|
|
--- |
|
|
|
|
|
| A |
d |
vance Authorization No. and Date |
|
Not issuedye |
|
t |
|
|
|
| S |
u |
bject |
|
Request of<br>dh |
|
M/s Hubergroup India Private Limited for fixation of<br>f th t dt Vtbl Oil bd Ftt |
|
|
|
|
|
|
|
a<br>But<br>(IT<br>20) |
oc norm<br>yl Ester<br>C HS Co |
s or e<br>(having 8<br>de – 2915 |
expor prouc - egeae<br>3% Lauric Acid and 22% No<br>9099) under Para 4.06 of HBP |
ase ay<br>rmal Butanol<br>Vol. I (2015- |
|
|
|
|
|
|
|
|
|
|
|
| D<br>fr |
ec<br>o |
ision:The Committee considered the cas<br>m the firm:<br>(i)<br>As per details given, L<br>can not contain Lauric<br> |
|
|
e as per a<br>auric Ac<br>Acid as<br> |
genda and |
it was decided to call for follow |
ing information |
|
|
|
|
|
|
|
id is con<br>stated i |
verted to Isopropyl Laurate, a<br>n Export. Please amend the |
s such export<br>description of |
|
|
|
Export product accordingly. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decision: The Committee considered the case as per agenda and it was decided to call for following information from the firm:
| Case No. |
Case No. |
Case No. |
Case No. |
A-06 |
A-06 |
A-06 |
A-06 |
A-06 |
A-06 |
A-06 |
A-06 |
A-06 |
A-06 |
|
Meeting No. |
|
|
NC/3/MEET/Mar/202122/15 |
|
|
|
|
|
|
|
|
|
| D |
|
|
|
1222 |
|
|
|
|
|
|
|
|
|
|
ate |
|
|
7.03.0 |
|
|
|
|
|
|
|
|
|
| F |
irm’s Name |
|
|
M/s Jindal Drugs Private Limited |
|
|
|
|
|
|
|
|
|
| H |
QF. No. |
|
|
<br>01/82/050/00053/AM19/DES-III |
|
|
|
|
|
|
|
|
|
| R |
LA F. No. |
|
|
03/94/040/00727/AM18 |
|
|
|
|
|
|
|
|
|
| A |
dvance Authorizati |
|
on No. and Date |
0310817723 dated 12.12.2017 |
|
|
|
|
|
|
|
|
|
| S |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ubject |
|
|
Request of M/s Jindal Drugs Private Limited for fixation of adhoc<br>it Ad Athiti N 0310817723 dtd |
|
|
|
|
|
|
|
|
|
|
|
|
|
norms agans vance uorzaon o.<br>12.12.2017 |
|
|
|
|
|
|
|
ae |
|
| D<br>4<br> <br>R |
**ecision:**The C<br>.07 of HBP Vol. I |
|
ommittee considered the request of firm and it was decided to ratify adhoc norms<br>as per details given below or as applied by the firm, whichever is less: |
|
|
|
|
|
|
|
|
under Para |
|
|
|
|
|
|
|
|
|
|
|
|
|
Qty.<br>1.02 kg |
|
|
Export product |
|
|
|
Qty. |
|
Sl.<br>No. |
|
Import items |
|
|
Qty. |
|
|
PURE<br>CINEOLE<br>(USP/BP)<br>/<br>EUCALYPTOL PURIFIED |
|
|
|
1 kg |
|
1 |
|
EUCALYPTOL<br>OIL<br>(INDUSTRIAL / COMMERCIAL<br>GRADE) |
|
|
1.02 kg |
|
|
A |
concerned maytake further necessaryaction asper a |
|
|
|
|
|
bove decision of NC. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Case No. |
A-07 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s Privi Organics India Limited |
| HQF. No. |
01/82/050/00387/AM19/DES-III |
| RLA F. No. |
03/95/040/00981/AM18 |
| Advance Authorization No. and Date |
0310819238 dated 19.02.2018 |
| Subject |
Request of M/s Privi Organics India Limited for enhancement in<br>the quantity of import item in respect of adhoc norms fixed<br>against Advance Authorization No. 0310819238 dated 19.02.2018 |
| **Decision:**The Committee considered the request of firm and it was decided to revise adhoc norms as under:<br> <br>Export product<br>Qty.<br>Sl.<br>No.<br>Import items<br>Qty.<br>Terpineol perfumery grade<br>1 kg<br>1<br>Alpha Pinene extrapure<br>1.36 kg<br>2<br>Phosphoric Acid<br>0.036 kg<br>RA concerned maytake further necessaryaction asper above decision of NC. |
|
| Case No. |
A-08 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s Piramal Enterprises Limited |
| HQF. No. |
01/82/050/01200/AM21/DES-III |
| RLA F. No. |
03/95/040/01217/AM20 |
| Advance Authorization No. and Date |
0310835767 dated 21.04.2020 |
| Subject |
Request of M/s Piramal Enterprises Limited for enhancement in<br>the quantity of import item in respect of adhoc norms fixed<br>against Advance Authorization No. 0310835767 dated 21.04.2020 |
| **Decision:**The Committee considered the request of the firm and it was decided to revise adhoc norms as under:<br>Sl.<br>No.<br>Export product<br>Qty.<br>Sl.<br>No.<br>Import items<br>Qty.<br>1<br>Clopidogrel Tablets USP 75mg<br>(Pack<br>Size<br>90<br>Tabs.)<br>(Each Tablet contains Clopidogrel<br>Bisulfate 97.875 mg equivalent to<br>clopidogrel base 75mg) (Net wt. of<br>Import Sr. No. 1 is 2466.45 kgs, Sr.<br>No. 2 is 280000 Nos, Sr. No. 4 is<br>280000 Nos.)<br>1 Number<br>Tablet<br>1<br>Clopidogrel Bisulphate<br>USP<br>101.626 mg<br>2<br>Plastic Bottles 75CC OPQ<br>white<br>HDPE<br>Round<br>38mm<br>Relevant as per<br>packing policy<br>4<br>CR38400APJT865 BLUE<br>PP465<br>1400<br>(Plastics<br>Caps/Closures PP 38MM-<br>400 Blue CR)<br>Relevant as per<br>packing policy<br>2<br>Clopidogrel Tablets USP 75mg<br>(Pack<br>Size<br>1000<br>Tabs.)<br>(Each Tablet contains Clopidogrel<br>Bisulfate 97.875 mg equivalent to<br>clopidogrel base 75mg) (Net wt. of<br>Import Sr. No. 1 is 9.79 kgs, Sr.<br>No. 3 is 100 Nos, Sr. No. 5 is 100<br>Nos.)<br>1 Number<br>Tablet<br>1<br>Clopidogrel<br>Bisulphate<br>USP<br>101.626 mg<br>3<br>CC8940AFS837 WHITE<br>PP551<br>CT<br>89<br>400SP<br>P/TS-R<br>White<br>(Plastic<br>Bottles 400CC OPQ white<br>HDPE Round 53mm)<br>Relevant as per<br>packing policy<br>5<br>Blue 53mm Pp Cap Lp-E<br>& Triseal F217hy Part ID<br>AC53400-BLP<br>(Plastics<br>Caps/Closures PP 53MM-<br>400 Blue PP)<br>Relevant as per<br>packing policy<br>Note: The above norms are valid only for subject to fulfillment of following conditions:<br>1.<br>The export product will be based on Dextro-Rotatory enantiomer of Clopidogrel racemate.<br>2.<br>The export will conform to Patent No. 1,338,777 of Apotex, Canada to which the firm is the<br>only Contract Manufacturing Unit.<br>3.<br>The manufacturing, testing and packaging will be approved by USFDA.<br>RA concerned maytake further necessaryaction asper above decision of NC. |
|
| Case No. |
A-09 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s Piramal Enterprises Limited |
| HQF. No. |
01/82/050/01017/AM20/DES-III |
| RLA F. No. |
03/95/040/01020/AM20 |
| Advance Authorization No. and Date |
0310834270 dated 17.01.2020 |
| Subject |
Request of M/s Piramal Enterprises Limited for enhancement in<br>the quantity of import item in respect of adhoc norms fixed<br>against Advance Authorization No. 0310834270 dated 17.01.2020 |
| **Decision:**The Committee considered the request of the firm and it was decided to revise adhoc norms as under:<br>Sl.<br>No.<br>Export product<br>Qty.<br>Sl.<br>No.<br>Import items<br>Qty.<br>1<br>Clopidogrel<br>Tablets<br>USP<br>75mg<br>(Pack Size 90 Tabs.) (Each Tablet<br>contains<br>Clopidogrel<br>Bisulfate<br>97.875 mg equivalent to clopidogrel<br>base 75mg) (Net wt. of Import Sr.<br>No. 1 is 2994.98 kgs, Sr. No. 2 is<br>340000 Nos, Sr. No. 4 is 340000<br>Nos.)<br>1 Number<br>Tablet<br>1<br>Clopidogrel Bisulfate USP<br>101.626 mg<br>2<br>Plastic Bottles 75CC OPQ white<br>HDPE Round 38mm<br>Relevant<br>as<br>per<br>packing<br>policy<br>4<br>CR38400APJT865<br>BLUE<br>PP465<br>1400<br>(Plastics<br>Caps/Closures PP 38MM-400<br>Blue CR)<br>Relevant<br>as<br>per<br>packing<br>policy<br>2<br>Clopidogrel Tablets USP 75mg (Pack<br>Size<br>1000<br>Tabs.)<br>(Each Tablet contains Clopidogrel<br>Bisulfate 97.875 mg equivalent to<br>clopidogrel base 75mg) (Net wt. of<br>Import Sr. No. 1 is 1370.25 kgs, Sr.<br>No. 3 is 14000 Nos, Sr. No. 5 is<br>14000 Nos.)<br>1 Number<br>Tablet<br>1<br>Clopidogrel Bisulfate USP<br>101.626 mg<br>3<br>CC8940AFS837 WHITE PP551<br>CT 89 400SP P/TS-R White<br>(Plastic Bottles 400CC OPQ<br>white HDPE Round 53mm)<br>Relevant<br>as<br>per<br>packing<br>policy<br>5<br>Blue 53mm Pp Cap Lp-E &<br>Triseal<br>F217hy<br>Part<br>ID<br>AC53400-BLP<br>(Plastics<br>Caps/Closures PP 53MM-400<br>Blue PP)<br>Relevant<br>as<br>per<br>packing<br>policy<br>Note: The above norms are valid only for subject to fulfillment of following conditions:<br>1.<br>The export product will be based on Dextro-Rotatory enantiomer of Clopidogrel racemate.<br>2.<br>The export will conform to Patent No. 1,338,777 of Apotex, Canada to which the firm is the only Contract<br>Manufacturing Unit.<br>3.<br>The manufacturing, testing and packaging will be approved by USFDA.<br>RA concerned maytake further necessaryaction asper above decision of NC. |
|
| Case No. |
A-10 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s Piramal Enterprises Limited |
| HQ F. No. |
01/82/050/01547/AM21/DES-III<br>01/82/050/01407/AM21/DES-III |
| RLA F. No. |
03/95/040/00283/AM21<br>03/95/040/00153/AM21 |
| Advance Authorization No. and Date |
0310837743 dated 18.08.2020<br>0310836784 dated 22.06.2020 |
| Subject |
Request of M/s Piramal Enterprises Limited for enhancement in<br>the quantity of import item in respect of adhoc norms fixed<br>against Advance Authorization No. 0310837743 dated 18.08.2020<br>and 0310836784 dated 22.06.2020 |
| **Decision:**The Committee considered the request of the firm and it was decided to revise adhoc norms as under:<br>For Advance Authorization No. 0310837743 dated 18.08.2020<br>Sl.<br>No.<br>Export product<br>Qty.<br>Sl.<br>No.<br>Import items<br>Qty.<br>1<br>Clopidogrel Tablets USP 75mg<br>(Pack Size 90 Tabs.) (Each Tablet<br>contains<br>Clopidogrel<br>Bisulfate<br>97.875<br>mg<br>equivalent<br>to<br>clopidogrel base 75mg) (Net wt. of<br>Import Item Sr. No. 1 is 6722.838<br>Kgs, Sr. No. 2 is 763200 Nos and<br>Sr. No. 4 is 763200 Nos.)<br>1<br>Number<br>Tablet<br>1<br>Clopidogrel Bisulfate USP<br>101.626 mg<br>2<br>Plastic Bottles 75CC OPQ<br>white HDPE Round 38mm<br>Relevant as<br>per packing<br>policy<br>4<br>CR38400APJT865<br>BLUE<br>PP465<br>1400<br>(Plastics<br>Caps/Closures PP 38MM-<br>400 Blue CR)<br>Relevant as<br>per packing<br>policy<br>2<br>Clopidogrel Tablets USP 75mg<br>(Pack Size 1000 Tabs.) (Each<br>Tablet<br>contains<br>Clopidogrel<br>Bisulfate 97.875 mg equivalent to<br>clopidogrel base 75mg) (Net wt. of<br>Import item Sr. No. 1 is 9.788<br>Kgs, Sr. No. 3 is 100 Nos and Sr.<br>No. 5 is 100 Nos.)<br>1<br>Number<br>Tablet<br>1<br>Clopidogrel Bisulfate USP<br>101.626 mg<br>3<br>CC8940AFS837<br>WHITE<br>PP551 CT 89 400SP P/TS-R<br>White<br>(Plastic<br>Bottles<br>400CC OPQ white HDPE<br>Round 53mm)<br>Relevant as<br>per packing<br>policy<br>5<br>Blue 53mm Pp Cap Lp-E &<br>Triseal<br>F217hy<br>Part<br>ID<br>AC53400-BLP<br>(Plastics<br>Caps/Closures PP 53MM-<br>400 Blue PP)<br>Relevant as<br>per packing<br>policy<br>Note: The above norms are valid only for subject to fulfillment of following conditions:<br>1. The export product will be based on Dextro-Rotatory enantiomer of Clopidogrel racemate.<br>2. The export will conform to Patent No. 1,338,777 of Apotex, Canada to which the firm is the<br>only Contract Manufacturing Unit.<br>3. The manufacturing, testing and packaging will be approved by USFDA. |
|
For Advance Authorization No. 0310836784 dated 22.06.2020
| Sl.<br>No. |
Export product |
Qty. |
Sl.<br>No. |
Import items |
Qty. |
| 1 |
Clopidogrel Tablets USP 75mg<br>(Pack Size 90 Tabs.) (Each<br>Tablet<br>contains<br>Clopidogrel<br>Bisulfate 97.875 mg equivalent to<br>clopidogrel base 75mg) (Net wt.<br>of Import Sr. No. 1 is 5285.25<br>kgs, Sr. No. 2 is 600000 Nos, Sr.<br>No. 4 is 600000 Nos.) |
1<br>Number<br>Tablet |
1 |
Clopidogrel Bisulfate USP |
101.626 mg |
|
|
|
2 |
Plastic Bottles 75CC OPQ<br>white HDPE Round 38mm |
Relevant as<br>per packing<br>policy |
|
|
|
4 |
CR38400APJT865<br>BLUE<br>PP465<br>1400<br>(Plastics<br>Caps/Closures PP 38MM-<br>400 Blue CR) |
Relevant as<br>per packing<br>policy |
| 2 |
Clopidogrel Tablets USP 75mg<br>(Pack Size 1000 Tabs.) (Each<br>Tablet<br>contains<br>Clopidogrel<br>Bisulfate 97.875 mg equivalent to<br>clopidogrel base 75mg) (Net wt.<br>of Import Sr. No. 1 is 9.79 kgs,<br>Sr. No. 3 is 100 Nos, Sr. No. 5 is<br>100 Nos.) |
1<br>Number<br>Tablet |
1 |
Clopidogrel Bisulfate USP |
101.626 mg |
|
|
|
3 |
CC8940AFS837<br>WHITE<br>PP551 CT 89 400SP P/TS-R<br>White (Plastic Bottles 400CC<br>OPQ white HDPE Round<br>53mm) |
Relevant as<br>per packing<br>policy |
|
|
|
5 |
Blue 53mm Pp Cap Lp-E &<br>Triseal<br>F217hy<br>Part<br>ID<br>AC53400-BLP<br>(Plastics<br>Caps/Closures PP 53MM-<br>400 Blue PP) |
Relevant as<br>per packing<br>policy |
| Note: The above norms are valid only for subject to fulfillment of following conditions:<br>1. The export product will be based on Dextro-Rotatory enantiomer of Clopidogrel<br>racemate.<br>2. The export will conform to Patent No. 1,338,777 of Apotex, Canada to which the firm is<br>the only Contract Manufacturing Unit.<br>3. The manufacturing, testing and packaging will be approved by USFDA. |
|
|
|
|
|
RA concerned may take further necessary action as per above decision of NC.
| Case No. |
Case No. |
A-11 |
A-11 |
A-11 |
A-11 |
| MeetingNo. |
|
NC/3/MEET/Mar/202122/15 |
|
|
|
| Date |
|
17.03.2022 |
|
|
|
| Firm’s Name |
|
M/s Oneiro Chemicals Ltd. |
|
|
|
| HQF. No. |
|
01/82/050/01394/AM17/DES-III |
|
|
|
| RLA F. No. |
|
34/24/040/00066/AM14 |
|
|
|
| Advance Authorization No. and Date |
|
3410037331 dated 03.07.2013 |
|
|
|
| Subject |
|
Request of M/s Oneiro Chemicals Ltd. for enhancement in the<br>quantity of import item in respect of adhoc norms fixed against<br>Advance Authorization No. 3410037331 dated 03.07.2013 |
|
|
|
| **Decision:**The Committee considered the request of firm and it was decided to revise adhoc no<br>Export Product<br>Qty.<br>Sl.<br>No.<br>Import Items<br>4,5,6,7-Tetrahydro<br>(3,2-C)<br>Thiono<br>Pyridine HCL<br>1 kg<br>1<br>Thiophene-2 Ethylamine<br>2<br>Methanol<br>3<br>Methyene Chloride<br>RA concerned may take further necessary action as per above decision of NC. |
|
|
of firm and it was decided to revise adhoc no |
|
rms as under:<br>Qty.<br>1.13 kg<br>1.356 kg<br>1.03 kg |
|
Export Product |
Qty. |
Sl.<br>No. |
Import Items |
Qty. |
|
4,5,6,7-Tetrahydro<br>(3,2-C)<br>Thiono<br>Pyridine HCL |
1 kg |
1 |
Thiophene-2 Ethylamine |
1.13 kg |
|
|
|
2 |
Methanol |
1.356 kg |
|
|
|
3 |
Methyene Chloride |
1.03 kg |
| Case No. |
A-12 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
| HQ F. No. |
01/82/050/01317/AM17/DES-III |
|
01/82/050/00217/AM19/DES-III |
| RLA F. No. |
09/24/040/00348/AM17 |
|
09/24/040/00430/AM18 |
| Advance Authorization No. and Date |
0910064196 dated 28.09.2016 |
|
0910065723 dated 07.12.2017 |
| Subject |
Request of M/s SRINI PHARMACEUTICALS PRIVATE |
|
LIMITED for enhancement in the quantity of import items in |
|
respect of norms fixed against Advance Authorization Nos. |
|
0910064196 dt. 28.09.2016 and 0910065723 dt. 07.12.2017 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal |
|
| Hearingto explain its case. |
|
| Case No. |
A-13 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
| HQF. No. |
01/82/050/01597/AM21/DES-III |
| RLA F. No. |
09/24/040/00642/AM19 |
| Advance Authorization No. and Date |
0910067796 dated 19.07.2019 |
| Subject |
Request of M/s Srini Pharmaceuticals Pvt. Ltd. for fixation of |
|
adhoc norms in respect of Advance Authorization No. |
|
0910067796 dated 19.07.2019 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal |
|
| Hearingto explain its case. |
|
| Case No. |
A-14 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
| HQF. No. |
01/82/050/00986/AM19/DES-III |
| RLA F. No. |
09/24/040/00036/AM19 |
| Advance Authorization No. and Date |
0910066244 dated 18.05.2018 |
| Subject |
Request of M/s SRINI PHARMACEUTICALS PRIVATE |
|
LIMITED for enhancement in the quantity of import items in |
|
respect of norms fixed against Advance Authorization No. |
|
0910066244 dated 18.05.2018 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal |
|
| Hearingto explain its case. |
|
| Case No. |
A-15 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
| HQF. No. |
01/82/050/00219/AM19/DES-III |
| RLA F. No. |
09/24/040/00459/AM19 |
| Advance Authorization No. and Date |
0910065758 dated 19.12.2017 |
| Subject |
Request of M/s SRINI PHARMACEUTICALS PRIVATE |
|
LIMITED for enhancement in the quantity of import items in |
|
respect of adhoc norms fixed against Advance Authorization No. |
|
0910065758 dated 19.12.2017 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal |
|
| Hearingto explain its case. |
|
| Case No. |
A-16 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
| HQF. No. |
01/82/050/00543/AM20/DES-III |
| RLA F. No. |
09/24/040/00269/AM20 |
| Advance Authorization No. and Date |
0910067906 dated 20.08.2019 |
| Subject |
Request of M/s SRINI PHARMACEUTICALS PRIVATE |
|
LIMITED for enhancement in the quantity of import items in |
|
respect of norms fixed against Advance Authorization No. |
|
0910067906 dated 20.08.2019 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal |
|
| Hearingto explain its case. |
|
| Case No. |
A-17 |
|
|
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
|
|
| Date |
17.03.2022 |
|
|
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
|
|
| HQF. No. |
01/82/050/01074/AM18/DES-III |
|
|
| RLA F. No. |
09/24/040/00309/AM18 |
|
|
| Advance Authorization No. and Date |
0910065528 dt. 29.09.2017 |
|
|
| Subject |
Request<br>of<br>M/s<br>SRINI |
PHARMACEUTICALS |
PRIVATE |
|
LIMITED for enhancement |
in the quantity of import items in |
|
|
respect of norms fixed against Advance Authorization No. |
|
|
|
0910065528 dt. 29.09.2017 |
|
|
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal |
|
|
|
| Hearingto explain its case. |
|
|
|
| Case No. |
A-18 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s Srini Pharmaceuticals Pvt Ltd, Hyderabad |
| HQF. No. |
01/82/050/00155/AM18/DES-III |
| RLA F. No. |
09/24/040/00649/AM17 |
| Advance Authorization No. and Date |
0910064785 dated 09.03.2017 |
| Subject |
Request of M/s Srini Pharmaceuticals Pvt Ltd, Hyderabad for<br>enhancement in the quantity of import item in respect of adhoc<br>norms fixed against Advance Authorization No. 0910064785 dated<br>09.03.2017 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal<br>Hearingto explain its case. |
|
| Case No. |
A-19 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
| Date |
17.03.2022 |
| Firm’s Name |
M/s SRINI PHARMACEUTICALS PRIVATE LIMITED |
| HQ F. No. |
01/82/050/00226/AM14/DES-III<br>01/82/050/00684/AM15/DES-III |
| RLA F. No. |
09/24/040/00017/AM14<br>09/24/040/00139/AM15 |
| Advance Authorization No. and Date |
0910055800 dated 19.04.2013<br>0910060467 dated 17.06.2014 |
| Subject |
Request of M/s Srini Pharmaceuticals Pvt. Ltd. for enhancement<br>of quanity of import items in respect of adhc norms fixed against<br>Advance Authorization No. 0910055800 dated 19.04.2013 and<br>0910060467 dated 17.06.2014 |
| **Decision:**The Committee considered the request of firm and it was decided to call the firm to attend Personal<br>Hearingto explain its case. |
|
| Case No. |
A-20 |
A-20 |
A-20 |
| MeetingNo. |
NC/3/MEET/Mar/202122/15 |
|
|
| Date |
17.03.2022 |
|
|
| Firm’s Name |
M/s Organica Aromatics |
|
|
| HQF. No. |
01/82/050/01034/AM09/DES-III |
01/82/050/01105/AM12/DES-III |
01/82/050/01612/AM09/DES-III |
| RLA F. No. |
07/24/040/00280/AM09 |
07/24/040/00314/AM12 |
07/24/040/00564/AM09 |
| Advance<br>Authorization<br>No. and Date |
0710059944 dt. 19.09.2008 |
0710084171 dt. 23.11.2011 |
0710062745 dt. 04.02.2009 |
| Subject |
Request of M/s Organica Aromatics for enhancement in the quantity of import items in respect of<br>adhoc norms fixed against Advance Authorization Nos. 0710059944 dated 19.09.2008, 0710084171<br>dated 23.11.2011 and 0710062745 dated 04.02.2009 |
|
|
| Decision:The Committee considered the request of firm it was decided to reject the request of firm for factory<br>visit. Further, it was also observed that earlier the firm has requested to furnish Central Excise Data for<br>Production / Consumption for the year 2008-09, 2009-10 and 2010-11, however the firm furnished the Central<br>Excise Data for Production / Consumption for the year2011-12, 2012-13 and 2013-14. Hence, it was decided<br>to call for following information from the firm:<br>(i)<br>Central Excise Data for Production / Consumption for the year 2008-09, 2009-10<br>and 2010-11.<br>(ii)<br>Sample Batch Record Data Sheet for the Export Period of the Licence from<br>Production Record certified by Chief Chemist indicating minimum and maximum<br>consumption in the Batch Record for the year 2008-2011. |
|
|
|
Meeting ended with thanks to Chair and participants
No analysis has been generated for this document yet.